NCT07576868 A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)
| NCT ID | NCT07576868 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Hyundai Bioscience Co., Ltd. |
| Condition | Dengue |
| Study Type | INTERVENTIONAL |
| Enrollment | 210 participants |
| Start Date | 2026-04-09 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 210 participants in total. It began in 2026-04-09 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.
Eligibility Criteria
Inclusion Criteria: * Patients who are 18 years or over of age at time of screening. * Patients who have at least two symptoms with a score of 2 or higher within 72 h from fever onset. * Patients who are diagnosed with dengue by NS1 positive (Phase 2- Part 1 only). And patients who are classified as dengue, zika, influenza, COVID-19 and others (Phase 3- Part 2 only) Exclusion Criteria: * Patients who show severe dengue (WHO dengue guideline C, any severe symptoms or clinical laboratory results) * Patients who have previously received dengue vaccine * Patients who have chronic medical conditions such as uncontrolled diabetes mellitus, severe asthma requiring oral steroids or admission to the hospital in the previous 6 months for cardiac disease
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07576868 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dengue. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07576868 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07576868 currently recruiting?
Yes, NCT07576868 is actively recruiting participants. Contact the research team at clinical@hyundaibio.com for enrollment information.
Where is the NCT07576868 trial being conducted?
This trial is being conducted at Hanoi, Vietnam, Mỹ Tho, Vietnam.
Who is sponsoring the NCT07576868 clinical trial?
NCT07576868 is sponsored by Hyundai Bioscience Co., Ltd.. The trial plans to enroll 210 participants.